Engflag

Solevita

Quick links to important sections

Solevita

Solevita_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solevita

Quick Facts

Property Description
Active ingredient St John's Wort (Hypericum perforatum L. extract)
Form Tablet, Capsule, Liquid extract, Oil
Pharmacological class Phytopharmaceutical, Natural Antidepressant/Anxiolytic Agent
Common use Relief of mild mood disturbances and nervous unrest
Origin Plant-derived

Defining Solevita: Type and Origin

Solevita is defined as a phytopharmaceutical and a traditional herbal medicinal product derived from the plant St John's Wort (Hypericum perforatum L.). This plant-derived product is typically structured as a single-active-ingredient product (monopreparation). The use of the St John's Wort extract is clinically recognized for its influence on mood and emotional balance, supporting its established role in traditional medicine.

The medicine's identity is intrinsically linked to its botanical source, where the extract is obtained from the flowering tops of the plant. As a phytopharmaceutical, it is classified within the Natural Antidepressant/Anxiolytic Agent pharmacological class. Solevita is often positioned for the adult patient group seeking natural support for temporary stress and feelings of tension, offering a non-synthetic option.

Composition and Available Forms

The active component in Solevita is the standardized Hypericum extract, containing primary bioactive constituents like Hypericin and Hyperforin. The product is commonly available for the oral route in dosage forms such as tablets or capsules, or as a liquid extract.

The extract is standardized to ensure a consistent level of these key compounds, an attribute that differentiates it from non-standardized herbal preparations. For preparations administered via the topical route, the extract may be incorporated into an oily base or other suitable pharmaceutical vehicle to create products like an oil or ointment, used for localized skin applications.

General Purpose: Mood and Nervous Rest

The general purpose of Solevita is to help stabilize and provide relief from temporary mood disturbances and associated symptoms of general nervous unrest. Within this typical use scenario, the product is used for temporary symptoms of stress and anxiety.

The product achieves its benefit by gently influencing the balance of mood chemicals in the nervous system, which supports emotional equilibrium. When prepared for topical application, the properties of the extract also lend themselves to the localized soothing of minor skin inflammation.

Regulatory References

  1. NIH Review

What side effects are possible with Solevita?

Official Side Effects and Safety Characteristics

Adverse reactions associated with St John's Wort extract are typically organized by System-Organ Class in regulatory documents. The officially listed effects are generally classified as Common or Uncommon.

Common reactions primarily involve Gastrointestinal Disorders (such as dry mouth, nausea, and upset stomach) and Psychiatric or Nervous System Disorders (including headache, dizziness, restlessness, agitation, and sleep disturbances). These effects may be more pronounced at the beginning of treatment.

Uncommon reactions include Skin and Subcutaneous Tissue Disorders, specifically allergic skin reactions and increased Photosensitivity (phototoxicity). The risk of severe photosensitivity is explicitly documented, requiring that individuals avoid intensive UV light exposure, such as sunbeds and prolonged sunbathing, while taking the oral preparation.

Classification Examples of Officially Listed Adverse Reactions
Common Headache, tiredness, restlessness, dry mouth, gastrointestinal discomfort
Uncommon Allergic skin reactions, severe photosensitivity/phototoxicity

Serious Safety Considerations The regulatory profile highlights two serious concerns: the potential for Severe Photosensitivity and the risk of Serotonin Syndrome when the extract is combined with certain other agents. The product label imposes a safety restriction against its use in individuals with severe endogenous depression.

Population Restrictions Safety documentation explicitly states that use is not recommended in children and adolescents under 18 years of age due to insufficient data. Similarly, the product is not recommended for use during pregnancy or breast-feeding due to a lack of adequate safety information for these populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Solevita identifies two primary toxicity risks: acute neurological effects and dose-dependent photosensitivity. Massive ingestion of the extract has been associated with reports of seizures and confusion as central nervous system manifestations. The profile also highlights that a severe risk is photosensitisation, which may lead to intensified sunburn-like symptoms and severe skin reactions in individuals exposed to strong sunlight or UV light, particularly in fair-skinned persons.

When to Seek Immediate Medical Help

Regulatory guidance mandates immediate action for severe systemic and neurological outcomes. Urgent medical attention is required for signs of a life-threatening allergic reaction, such as difficult breathing or swelling of the face or throat. Similarly, a healthcare professional must be contacted at once if symptoms consistent with Serotonin Syndrome (e.g., agitation, fast heart rate, hyperthermia) are present, which are classified as severe regulatory concerns.

Overdose Management

Management of overexposure is defined as symptomatic and supportive treatment, as no specific antidote is known. Following a confirmed or suspected massive ingestion, the patient must be protected from sunlight and other UV-light sources for one to two weeks to mitigate the severe dermatological risk. Hospital monitoring is implied for cases involving massive ingestion to manage these acute events.

Therapeutic Uses of Solevita

What Solevita Treats: Main Uses and Benefits

The therapeutic application of Solevita, derived from St John's Wort extract, focuses primarily on supportive relief for psychological distress and traditional external aid for minor physical manifestations. This dual therapeutic scope encompasses both internal and external applications.

Relief of Mild Mood and Emotional Symptoms

Internally, Solevita is commonly used across conditions characterized by symptoms related to systemic imbalance, episodic symptoms of low mood, and symptoms related to heightened physiological activity. The extract is considered relevant in contexts where patients experience symptoms related to increased physiological stress, restlessness, and mild sleep issues. Its benefit offers symptomatic relief that supports patients during episodes of heightened discomfort related to stress and provides supportive relief when symptoms interfere with routine activities.

Traditional Support for Minor Skin Irritations

In its external form, Solevita is used across domains involving minor tissue disruption, such as minor inflammations of the skin, superficial abrasions, and slight skin discomfort. When applied to localized areas, it may assist with easing symptoms related to inflammatory or irritative states and provides supportive relief when symptoms interfere with routine activities related to minor skin injuries.

“This product may be part of symptomatic management, offering supportive relief that helps ease the overall symptom burden.”

Quick Fact: Relief for Symptoms Related to Systemic Imbalance and Heightened Physiological Activity

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Solevita — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for products containing St John's Wort (Hypericum perforatum L. extract), as defined by governmental regulatory sources.

Eligibility Scope Status Based on Official Labeling
Populations for whom use is allowed Adults (18 years and older) for oral use. The elderly are generally included.
Populations for whom use is contraindicated Patients with known hypersensitivity to the active ingredient. Patients diagnosed with Severe Depression or major psychiatric disorders.
Age-related eligibility rules Not recommended for children and adolescents under 18 years for oral use due to insufficient safety and efficacy data.
Pregnancy and lactation eligibility Use is not recommended during pregnancy or breastfeeding due to a lack of sufficient safety data.
Conditional eligibility restrictions Patients must avoid intense UV light exposure (e.g., sunbeds) due to the risk of photosensitivity. Discontinuation is required at least two weeks prior to any scheduled surgery.

Official Eligibility Structure

Regulatory documents define the user profile for Solevita as being strictly limited to adults with mild mood disturbances. This eligibility profile explicitly excludes populations with severe underlying psychiatric disease and those for whom safety data is insufficient, such as children, adolescents, and women who are pregnant or breastfeeding. Furthermore, use is subject to conditional restrictions, including the avoidance of intense UV light and temporary discontinuation before surgery.

What should I know about interactions with other medicines?

The official interaction profile of Solevita (St John's Wort) is structured around two principal interaction types as defined in government regulatory documents. The primary mechanism is Enzyme Induction of Cytochrome P450 (CYP) isoenzymes (CYP3A4, CYP2C9, CYP2C19) and Transporter Induction of P-glycoprotein (P-gp). This pharmacokinetic interaction causes a documented reduction of plasma concentrations and systemic exposure for many co-administered medicines. The full induction effect persists and requires monitoring for approximately one to two weeks after discontinuation.

This reduction in exposure forms the basis for regulatory classification of numerous combinations as contraindicated, due to the high risk of loss of therapeutic effect.

Official Interaction Statements

  • The co-administration is contraindicated with Immunosuppressants (e.g., Ciclosporin), HIV Antivirals (e.g., Indinavir), and certain Anticoagulants (e.g., Warfarin) due to the risk of therapeutic failure.
  • Combining the product with oral hormonal contraceptives is officially documented to lead to reduced effectiveness and potential for unintended pregnancy.
  • A pharmacodynamic interaction exists with other serotonergic agents (e.g., SSRIs, Triptans), which is documented to increase the official risk of Serotonin Syndrome.

Connection to the overall interaction profile

The regulatory documentation formally establishes that the product's interaction structure is defined by its ability to induce key metabolic enzymes and transport proteins, resulting in a systemic pharmacokinetic interaction that reduces the exposure of numerous co-administered medicinal products. These two documented effects form the strict basis for official restrictions and contraindicated combinations found in government labels.

Mechanism of Action

How Solevita Works

Multi-Transporter Neurochemical Modulation

The primary mechanism involves the robust, non-selective inhibition of central nervous system transporters for Serotonin, Norepinephrine, and Dopamine by Hyperforin. By blocking the reuptake of these key neurotransmitters back into the synapse, this action immediately enhances monoaminergic signaling, creating a state of enhanced neurochemical stability .

Neuroendocrine and Adaptive Stress Regulation

The extract's constituents regulate the Hypothalamic-Pituitary-Adrenal (HPA) axis, which governs the body's neuroendocrine stress response, and influence neural receptor sensitivity (e.g., 5-HT2 receptors). The functional consequence of this adaptive modulation is the regulation of stress hormone feedback and the long-term adjustment of the physiological response to stressors.

Complementary Localized Enzyme Inhibition

A separate mechanism involves the localized inhibition of enzymes like microsomal Prostaglandin E2 synthase-1 (mPGES-1) and 5-Lipoxygenase (5-LO). This activity is utilized to modulate inflammatory pathways, which provides a physiological basis for the extract’s ability to modulate localized eicosanoid activity and reduce tissue-level signaling.

Dosage and Administration Information

Instruction Map: How to use Solevita — Administration Guidelines

Solevita, derived from a standardized Hypericum perforatum extract, is administered following specific routes and dosing patterns, primarily for short-term use.

Administration Scope

Category Instruction Detail
Route of administration Oral (tablets, capsules, liquid extract) for systemic use; Topical/Dermal (oils) for localized application.
Dosing schedule Oral: Adult daily dose typically ranges from 600 mg to 1200 mg of the standardized dry extract. A common regimen is 300 mg twice daily or 600-900 mg once daily, depending on the specific preparation.
Timing in relation to meals Oral preparations are typically taken with a liquid and independent of food. Doses are commonly scheduled for morning and evening to maintain consistent exposure.
Preparation requirements Tablets and capsules should be swallowed whole. Topical preparations are applied undiluted to the affected skin area.
Age-group administration rules Oral use is generally restricted to adults and adolescents over 12 years of age. Use in children under 12 years is not recommended.
Missed-dose rules If a scheduled dose is missed, it is advised to take the next dose at the usual time and not take a double dose.
Special procedural conditions Duration of use for mood symptoms is typically limited to 4 to 6 weeks to assess response, with use beyond 3 months requiring professional consultation.

Instruction Classifications (High-Level)

Category Classification Detail
Administration method type Oral and Topical.
Frequency pattern Daily (once or twice per day for oral forms).
Basis of use Standardized herbal application of Hypericum perforatum L.
Use-context constraints Short-term use for defined periods.

Resulting Procedural Structure

Step sequence:

  • Take the standardized oral dose (e.g., 300 mg) twice daily (morning and evening).
  • Swallow the oral form with water.
  • Topical forms are applied thinly to the skin as needed.

Connection to the overall use protocol: Instructions establish a standardized protocol by defining the accepted routes, mandating a consistent daily dose and frequency, and clearly outlining the age limitations and expected short-term duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solevita

The available information regarding Solevita (St John’s Wort extract) focuses on research describing its use for temporary mood disturbances and its traditional application for minor skin irritations. The research landscape comprises different types of studies, including controlled trials and traditional documentation, which together contribute to the landscape of what has been studied—and what remains uncertain—regarding this product.

Evidence for Use in Mild Mood Disturbances and Nervous Unrest

The research base for the internal use of St John’s Wort extract has focused on conditions characterized by fluctuating or episodic manifestations, such as mild mood disturbances and symptoms of nervous unrest. The primary evidence comes from numerous Randomized Controlled Trials (RCTs), conducted as double-blind studies where the extract was studied for its role in adult populations diagnosed with mild to moderately-severe depressive disorders. These studies often compared the extract against an inactive substance (placebo) or against other active comparators.

The outcomes that researchers examined included tracking changes in the severity of symptoms using standardized clinical scales, such as the Hamilton Depression Rating Scale, which is relevant in evidence describing how symptoms are measured. These studies explored short-term symptom changes, typically over time intervals of 4 to 12 weeks.

Findings describe patterns observed in the studies where patterns related to symptoms were observed in the study populations during the study period. Because these studies were often short-term, the research provides insight into the short-term changes that were measured during the study. However, the data collected in these trials are complex. Findings were mixed across some studies, and the synthesis of results shows patterns related to specific symptom axes, findings describe group patterns, not personal outcomes.

Research Base for Traditional Topical Use in Minor Skin Irritations

The evidence supporting the external, traditional use of the extract for minor skin discomfort and irritations is structured differently. This application was evaluated in a research context that relies heavily on Traditional Use Assessments, which document long-standing historical experience with the extract.

Supporting data for the topical form includes laboratory studies and observational studies, where researchers examined characteristics related to conditions linked to inflammatory or irritative states. The outcomes monitored in these settings include those related to physical discomfort and outcomes linked to inflammatory or irritative states, such as measuring the time required for resolution of minor skin discomfort or assessing wound healing progression.

This research highlights changes measured during the study period in localized areas. However, this evidence base is limited in contemporary, large-scale clinical trials. The regulatory framework for this use acknowledges the historical context, but the evidence base includes different study types, and many findings are derived from settings that are not controlled RCTs.

Durability of Effect and Long-Term Follow-up

Most core clinical research involving the internal use of Solevita has focused on research exploring short-term symptom changes, with follow-up durations typically ranging from 4 to 12 weeks. This design provides information about the patterns observed over relatively limited time intervals.

Consequently, long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of any observed changes or the patterns of use over six months or longer. Existing studies provide limited insight into how symptoms may evolve in patients using the extract for extended periods, and there is a need for more data derived from settings with longer follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Solevita (FAQ)

Q: How quickly does Solevita start working for overactive bladder symptoms?

Official product information states that Solevita (St John's Wort) is indicated for the relief of mild mood disturbances and nervous unrest, not for overactive bladder symptoms. For its indicated use, studies and official product information suggest that the effects are typically evaluated after a period of four to six weeks of consistent use.

Q: What makes Solevita different from other medicines that treat bladder control issues?

Solevita is classified as a phytopharmaceutical and contains St John's Wort extract, a plant-derived ingredient. It is officially indicated for temporary mild mood disturbances and nervous unrest. Medicines used to treat bladder control issues usually contain synthetic ingredients and have a different mechanism of action and different intended uses.

Q: What are the most commonly reported mild side effects of Solevita?

According to official regulatory documents, the most commonly reported side effects include gastrointestinal symptoms such as upset stomach, nausea, or dry mouth. Other common reactions are nervous system disorders, including headache, dizziness, restlessness, agitation, and problems with sleep.

Q: What should I do if I accidentally miss a dose of Solevita?

Official administration instructions state that if a dose is missed, regulatory guidance advises against taking a double dose to compensate. Instead, the instruction is to simply take the next dose at the usual scheduled time. This approach is designed to maintain a consistent dosing schedule.

Q: Is there any connection between Solevita and glaucoma?

Official product warnings focus primarily on potential severe drug interactions, the risk of Serotonin Syndrome, and severe photosensitivity. Specific warnings or contraindications related to the eye condition glaucoma are not listed in the regulatory documents for St John's Wort extract.

Q: Can Solevita interact with antidepressants or mood stabilizers?

Yes, regulatory documents note a significant interaction risk. Combining Solevita with other serotonergic agents (a class that includes many types of antidepressants) is documented to increase the official risk of Serotonin Syndrome, which can be serious. Reviewing all medications with a healthcare provider is generally recommended due to the interaction risks.

Q: Can the effectiveness of Solevita decrease over time with continued use?

Most clinical research involving Solevita has focused on short-term use, typically 4 to 12 weeks. Because of this, official information indicates that the long-term effects, including whether the effect might diminish (called tolerance or tachyphylaxis), are not fully established in the research.

Q: What is the difference between Solevita and Solifenacin?

These are two separate and different medicinal products. Solevita contains St John's Wort extract and is indicated for mood symptoms. Solifenacin is a synthetic prescription drug used to treat overactive bladder symptoms and has a distinct mechanism of action.

Q: How long do the initial side effects of Solevita usually last?

Official product information notes that common adverse reactions, such as mild gastrointestinal issues or headache, may be more noticeable at the beginning of treatment. However, the regulatory label does not specify an exact number of days or weeks for these initial side effects to reliably subside.

Q: Are there any signs of a serious allergic reaction to Solevita I should be aware of?

While allergic skin reactions are listed as uncommon, regulatory documents emphasize the need to be aware of the signs of Severe Photosensitivity (an intense sunburn-like reaction) and the potential for Serotonin Syndrome when combined with other drugs. Patients should be aware of the signs of severe reactions, and any concerns require prompt professional evaluation.

Q: Can taking Solevita cause dry mouth, and what helps relieve it?

Dry mouth is listed as a common gastrointestinal adverse reaction in official product information. Although regulatory documents list the side effect, they do not provide specific, documented advice or instructions on simple relief strategies.

Q: Does Solevita interact with common over-the-counter pain relievers like ibuprofen?

Official documentation lists contraindications for many prescription drug classes (like anticoagulants and immunosuppressants) due to enzyme induction. It does not typically list Ibuprofen as a contraindicated drug. Due to the potential for enzyme induction, discussing all co-administered products with a healthcare professional is recommended.

Q: Should I avoid certain vitamins or herbal supplements while on Solevita?

Official guidance advises caution, particularly regarding other herbal products or supplements that may affect serotonin levels, as this increases the risk of Serotonin Syndrome. Reviewing the use of all supplements with a professional is recommended to avoid potentially reducing the effectiveness of other medications being taken.

Q: Can I drink alcohol while taking Solevita, and if so, how much is safe?

Regulatory guidance advises patients to avoid or limit the consumption of alcohol while using Solevita. This precaution is advised because alcohol may increase or potentiate the central nervous system side effects of the medicine, such as drowsiness or dizziness.

Q: What are the signs of having taken too much Solevita (overdose symptoms)?

Regulatory information on overdose suggests that symptoms may include an exaggeration of known side effects, such as dry mouth, nausea, vomiting, dizziness, and confusion. There is also a documented risk of developing increased sensitivity to sunlight (photosensitivity) following a high dose.

Q: Is it possible for Solevita to cause hallucinations or unusual dreams?

Official adverse reaction lists include general nervous system effects like restlessness, agitation, and sleep disturbances. While hallucinations are not typically listed as a common or uncommon side effect of Solevita alone, severe psychiatric symptoms can be a sign of the documented, rare risk of Serotonin Syndrome.

How should Solevita be stored and disposed of?

How to Store and Dispose of Solevita

The storage and disposal of Solevita must strictly adhere to the conditions mandated by regulatory labeling to maintain the stability of the St John's Wort extract and ensure safety.

Official Storage Requirements

Solevita must be stored below 25 C or the temperature specified on the label, and it is a mandatory instruction to Do not freeze the product. It must be protected from light and moisture; therefore, it should be kept in the original container or outer carton.

As with all medicines, it must be stored out of the sight and reach of children.

Disposal

Unused or expired Solevita must not be thrown away via wastewater or household waste. The medicine should be disposed of by taking it to a community drug take-back program or following other local regulatory requirements for the disposal of unused medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Solevita found in:

A-Z Index: